

[REDACTED]

From: Parr R (Rose Marie)
Sent: 11 June 2019 12:51
To: [REDACTED] NHS ENGLAND & NHS IMPROVEMENT - X24
Cc: [REDACTED] Chief Medical Officer; Calderwood C (Catherine); [REDACTED]
Subject: RE: NHS Review

Hi [REDACTED]
Many thanks for this - totally agree with this approach – and look forward to discussing in more detail at our meeting on Friday.
Kindest regards
Rose Marie

From: [REDACTED] NHS ENGLAND & NHS IMPROVEMENT - X24 [REDACTED]
Sent: 11 June 2019 12:36
To: Parr R (Rose Marie) <RoseMarie.Parr@gov.scot>
Cc: [REDACTED] Chief Medical Officer <CMO@gov.scot>; Calderwood C (Catherine) <Catherine.Calderwood@gov.scot>; [REDACTED]
Subject: Re: NHS Review

Rose Marie

Thanks. Perhaps my email wasn't that clear. Apologies. I was thinking the UK CPhO group should also discuss this as a group first, bearing in mind we have a commitment to deliver the report by end of June and are already fully committed with interviews and so forth. I can see that once that report is delivered we can also work with you on an addendum that's submitted in due course.

Let's discuss on Friday

[REDACTED]

Sent from my iPhone

On 11 Jun 2019, at 12:24, "RoseMarie.Parr@scotland.gsi.gov.uk" <RoseMarie.Parr@scotland.gsi.gov.uk> wrote:

Dear [REDACTED]

Many thanks for your email here – and I look forward to our UK CPO meeting in London on Friday.

On the cannabis item, you rightly say that our CMO in Scotland has had some recent discussion with [REDACTED] regarding this process review and its scope across the UK.

I understand then, that an offer has been made for Scotland to be included in this Review. As this Review has come about as part of the UK regulatory changes - we feel it is sensible to include Scotland at this stage, and in particular with the knowledge that NI is now taking part. This seems a sound way forward .

I hope this is helpful and have copied colleagues in Wales, NI and Scotland into this email for awareness.

Best wishes
Rose Marie

From: [REDACTED] (NHS ENGLAND & NHS IMPROVEMENT - X24) [REDACTED]
Sent: 10 June 2019 17:23
To: [REDACTED]
Cc: [REDACTED] Parr R (Rose Marie) <RoseMarie.Parr@gov.scot>
Subject: Re: Agenda UK CPhO's Meeting 14 June 2019

On cannabis, we need to discuss the “process review” now well underway, and whether DAs wish to be included, now that NI is in. Rose Marie - I'm aware there has been a discussion with CMO Scotland.

Sent from my iPhone

This e-mail (and any files or other attachments transmitted with it) is intended solely for the attention of the addressee(s). Unauthorised use, disclosure, storage, copying or distribution of any part of this e-mail is not permitted. If you are not the intended recipient please destroy the email, remove any copies from your system and inform the sender immediately by return.

Communications with the Scottish Government may be monitored or recorded in order to secure the effective operation of the system and for other lawful purposes. The views or opinions contained within this e-mail may not necessarily reflect those of the Scottish Government.

Tha am post-d seo (agus faidhle neo ceanglan còmhla ris) dhan neach neo luchd-ainmichte a-mhàin. Chan eil e ceadaichte a chleachdadh ann an dòigh sam bith, a' toirt a-steach còraichean, foillseachadh neo sgaoileadh, gun chead. Ma 's e is gun d'fhuair sibh seo gun fhiosd', bu choir cur às dhan phost-d agus lethbhreac sam bith air an t-siostam agaibh agus fios a leigeil chun neach a sgaoil am post-d gun dàil.

Dh'fhaodadh gum bi teachdaireachd sam bith bho Riaghaltas na h-Alba air a chlàradh neo air a sgrùdadh airson dearbhadh gu bheil an siostam ag obair gu h-èifeachdach neo airson adhbhar laghail eile. Dh'fhaodadh nach eil beachdan anns a' phost-d seo co-ionann ri beachdan Riaghaltas na h-Alba.

This message may contain confidential information. If you are not the intended recipient please inform the sender that you have received the message in error before deleting it. Please do not disclose, copy or distribute information in this e-mail or take any action in relation to its contents. To do so is strictly prohibited and may be unlawful. Thank you for your co-operation.

NHSmail is the secure email and directory service available for all NHS staff in England and Scotland. NHSmail is approved for exchanging patient data and other sensitive information with NHSmail and other accredited email services.

For more information and to find out how you can switch, <https://portal.nhs.net/help/joiningnhsmail>

This email has been scanned by the Symantec Email Security.cloud service.

For more information please visit <http://www.symanteccloud.com>

From: Parr R (Rose Marie) <RoseMarie.Parr@gov.scot>

Sent: 20 June 2019 10:40

To: [REDACTED]

Cc: [REDACTED]

Subject: FW: NHS Process Review -Cannabis

Dear All

Please see the email below and the attached- for further discussion .

Best wishes

Rose Marie

Sent with BlackBerry Work

(www.blackberry.com)

From: [REDACTED] (NHS ENGLAND & NHS IMPROVEMENT - X24) <[REDACTED]>

Date: Thursday, 20 Jun 2019, 10:18 am

To: Parr R (Rose Marie) <RoseMarie.Parr@gov.scot>, [REDACTED]

Cc: [REDACTED] (NHS ENGLAND & NHS IMPROVEMENT - X24)

[REDACTED] (NHS ENGLAND & NHS IMPROVEMENT - X24)

Subject: Re: NHS Process Review -Cannabis

Rose Marie, [REDACTED]

Please find attached the Terms of Reference and background briefing (including methodology) for the Cannabis process review.

Kind Regards,

[REDACTED]
[REDACTED]
Medicines Policy Lead
Medicines and Diagnostics Policy Unit
5W05 Quarry House
[REDACTED]

From: rosemarie.parr@scotland.gsi.gov.uk

Sent: Friday, June 14, 2019 8:14 pm

To: [REDACTED] (NHS ENGLAND & NHS IMPROVEMENT - X24)

Cc: [REDACTED] <[REDACTED]@scotland.gsi.gov.uk>;

catherine.calderwood@scotland.gsi.gov.uk; [REDACTED] (SCOTTISH GOVERNMENT)

HEALTH & SOCIAL CARE DIRECTORATE); [REDACTED]
[REDACTED]
[REDACTED] (SCOTTISH GOVERNMENT HEALTH
& SOCIAL CARE DIRECTORATE)

Subject: NHS Process Review -Cannabis

Dear [REDACTED]

Many thanks for hosting the UK CPO meeting this afternoon and for the update on the process review on Cannabis commissioned by your SoS.

As discussed -in principle Scotland would like to be included in this review- however I understand that the work in NHS England (and now including NI patients) is at an advanced stage and that the report is due by the end of this month.

Nonetheless - and in order to be as inclusive as possible - as we discussed it would be good to see your background briefing and methodology for evidence gathering- [REDACTED]

[REDACTED]

Many thanks again and I look forward to hearing from you or appropriate colleagues with the relevant details.

I have copied our CMO into this for information and awareness- following recent discussions.

Best wishes
Rose Marie

Sent with BlackBerry Work
(www.blackberry.com)

EXTRACT FROM LETTER DATED 01/08/2019 TO MEMBER OF PUBLIC

NHS England Process Review

Following the meeting, you have asked why [REDACTED] was not included in the review on accessing CBPMs. The process review underway in NHS England aims to identify any potential barriers to accessing CBPMs on the NHS in England and consider how to address them where they may exist.

As this review is on NHS England processes only, it was not appropriate for Scottish patients to be considered. I understand, however, that patient consent forms were issued to Scottish patients in error, which will have understandably caused some confusion about the geographical scope of the review. But, even though the review relates to England, the Scottish Government will of course consider its findings and whether they are relevant to any unnecessary barriers to access that may exist in NHS Scotland.



T: 0300 244 4000
E: scottish.ministers@gov.scot

[redacted]

Sent by email to:
[redacted]

Your ref: ZA9910/PFW
Our ref: 2019/0024064
August 2019

Thank you for your letter of 7 August addressed to the First Minister on behalf of [redacted]. I am replying as the Minister with portfolio responsibility for this area.

I note from your letter that you say [redacted] has been excluded from a trial in NHS England because she resides in Scotland. I am not aware of any current trials for CBPMs taking place in England which [redacted] could be eligible for. I would, however, be happy to look into this further and let you have a further response if you provide me with details for the trial.

It may be that [redacted] is referring to the recent NHS England process review. Earlier this year, the Secretary of State for Health and Social Care commissioned NHS England to carry out a process review to identify any potential barriers to accessing CBPMs on the NHS in England. The aims of the review were threefold: to identify the potential barriers to the appropriate prescribing of CBPMs; to identify any changes that could be put in place to support appropriate prescriptions of CBPMs in future; and to identify ways to facilitate the building of an evidence base for the use of CBPMs.

As this review was about NHS England processes, it was not appropriate for Scottish processes to be considered. I understand, however, patient consent forms were initially issued to some Scottish patients in error and this has likely caused some unintended confusion. Notwithstanding the formal focus on NHS England, the Scottish Government will, of course, consider the outcome of the review and how the findings might address any barriers to access in NHS Scotland where they may exist.

Details of the outcome of the review were published by NHS England on 8 August 2019 and a copy can be found at <https://www.england.nhs.uk/wp-content/uploads/2019/08/barriers-accessing-cannabis-based-products-nhs-prescription.pdf>

Scottish Ministers, special advisers and the Permanent Secretary are covered by the terms of the Lobbying (Scotland) Act 2016. See www.lobbying.scot



I hope you find this information helpful.

JEANE FREEMAN


Scottish Ministers, special advisers and the Permanent Secretary are covered by the terms of the Lobbying (Scotland) Act 2016. See www.lobbying.scot

St Andrew's House, Regent Road, Edinburgh EH1 3DG
www.gov.scot



INVESTORS
IN PEOPLE

Accredited
Until 2020





T: 0300 244 4000
E: scottish.ministers@gov.scot

[redacted]

July 2019

Thank you for your email regarding the NHS England process review about the prescribing of Cannabis Based Products for Medicinal Use (CBPMs).

Earlier this year, the Secretary of State for Health and Social Care commissioned NHS England to carry out a process review to identify any potential barriers to accessing CBPMs on the NHS in England. The aims of the process are threefold: to identify the potential barriers to the appropriate prescribing of CBPMs; to identify any changes that could be put in place to support appropriate prescriptions of CBPMs in future; and, to identify ways to facilitate the building of an evidence base for the use of CBPMs.

As this review is about NHS England processes, it was not appropriate for Scottish processes to be considered. I understand, however, patient consent forms were issued to Scottish patients in error, and this will likely have caused some unintended confusion. Notwithstanding the formal focus on NHS England, the Scottish Government will of course consider the outcome of the review and how the findings might address any barriers to access in NHS Scotland where they may exist.

I hope you find this information helpful.

Jeane Freeman

Scottish Ministers, special advisers and the Permanent Secretary are covered by the terms of the Lobbying (Scotland) Act 2016. See www.lobbying.scot

St Andrew's House, Regent Road, Edinburgh EH1 3DG
www.gov.scot



INVESTORS
IN PEOPLE

Accredited
Until 2020

